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We have shown the full prevention of mesangial expansion in insulin-deficient diabetic rats by treatment with clinically-relevant
dosages of glibenclamide (Glib). Studies in mesangial cells (MCs) also demonstrated reduction in the high glucose (HG)-induced
accumulation of collagens, proposing that this was due to increased catabolism. In the present study, we investigated the signaling
pathways that may be implicated in Glib action. Rat primary MCs were exposed to HG for 8 weeks with or without Glib in
therapeutic (0.01 μM) or supratherapeutic (1.0 μM) concentrations. We found that HG increased collagen IV protein accumulation
and PAI-1 mRNA and protein expression, in association with decreased cAMP generating capacity and decreased PKA activity.
Low Glib increased collagen IV mRNA but fully prevented collagen IV protein accumulation and PAI-1 overexpression while
enhancing cAMP formation and PKA activity. MMP2 mRNA, protein expression and gelatinolytic activity were also enhanced.
High Glib was, overall, ineﬀective. In conclusion, low dosage/concentration Glib prevents HG-induced collagen accumulation in
MC by enhancing collagen catabolism in a cAMP-PKA-mediated PAI-1 inhibition.

1. Introduction
We have reported the complete prevention of glomerular
mesangial expansion and increased albuminuria by the
long-term administration of sulfonylureas in streptozotocindiabetic rats [1]. This prevention was induced by low
drug dosages glibenclamide (Glib, or glyburide) 0.28 mg/Kg
(0.04 mg/Kg if adjusted for diﬀerences in drug clearance
rates between rats and humans [2]) as compared to those
clinically administered (0.018–0.286 mg/Kg). The protective
eﬀect occurred without improvement in glycemia, renal
hypertrophy, or glomerular hyperfiltration. Thus, the reasons for these unexpected findings were not apparent.
One of the most characteristic alterations of diabetic
nephropathy is the accumulation of mesangial extracellular matrix (ECM) [3]. While both short- and long-term
exposure of mesangial cells (MC) to high glucose (HG)
result in collagen medium accumulation [4], the metabolic
alterations responsible appear dissimilar. Short-term exposure primarily stimulates synthesis of ECM components.
This is in great part controlled by TGF-β action [5, 6] and

mediated by activation of multiple diacylglycerol-sensitive
protein kinase-C (PKC) isoforms [4, 7]. In contrast, longterm exposure results in a persistent collagen accumulation
that is mainly due to reduced catabolism. Further, this is
singularly PKC-δ-driven and TGF-β-independent [4].
Sulfonylureas close the plasma membrane ATP-sensitive
K+ channels (KATP ) resulting in the depolarization and
activation of voltage-dependent calcium channels, thus
triggering [iCa2+ ]-dependent reactions. The KATP channel is
formed by two sets of four subunits each. One is the poreforming, inwardly rectifying K+ channel (Kir6.1 or Kir6.2)
and the other is the regulatory sulfonylurea receptor SUR1
or SUR2 (SUR2A and its variant SUR2B). Various combinations of Kir6.x and SURx result in large heterogeneity
of KATP channels providing tissue-specific channel activity
[8]. Specific channels posses distinct cellular localization,
electrophysiological properties, nucleotide sensitivity, and
response to diverse channel inhibitors or channel openers
[9, 10]. This distinct behavior includes diﬀerences in the
aﬃnity for specific sulfonylureas [11]. Sulfonylureas freely
cross the cell membrane and therefore they may bind to both
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the cytoplasmic side of the membrane-associated SUR and to
the SUR components of intracellular KATP channels [9].
Two binding components with diﬀerent aﬃnities to Glib
and pharmacological properties have been described in rat
glomeruli [12]. We have also demonstrated the presence
of functional plasma membrane KATP channels in rat MC
[13]. Two MC channels were identified as comprised by
Kir6.1 in complex with either SUR2B or with a unique
mesangial SUR2 splice variant (mcSUR2B) [14]. Although
the physiological role of these channels remains unknown,
sulfonylureas modify MC metabolism. Acute treatment (72
hours) of MC in culture with high concentrations (1.5 mM)
of the sulfonylurea tolazamide resulted in augmented GLUT1
glucose transporter expression, enhanced glucose uptake,
and increased synthesis and medium accumulation of collagen [15]. These changes could be demonstrated under
physiological glucose concentrations and after 12- to 14-day
exposure to HG.
We have also tested the eﬀects of treatment of MC
with increasing concentrations of Glib in MC in culture
exposed for long periods (8 weeks) to HG [16]. As in
the animal model, Glib treatment at low concentrations
prevented the HG-induced accumulation of ECM. Although
the mechanism for this change was undetermined, it was
proposed that a Glib enhanced matrix catabolism [16]. In the
present study we explored how chronic treatment with Glib
may alter HG-induced accumulation of collagen IV.

2. Materials and Methods
2.1. Cell Culture. Primary cultures of MC were obtained
from outgrowths of isolated glomeruli from Munich-Wistar
rats and grown and identified as described [14]. The study
was approved by the Henry Ford Health System Institutional
Animal Care and Use Committee (IACUC) in accord with
the National Institutes of Health Guidelines for the Care
and Use of Laboratory Animals. Cells were grown in RPMI
medium 1640, pH 7.4, containing 5 mM glucose, 2 mM Lglutamine, 23.8 mM NaHCO3 , 15% FBS, 5 U/mL penicillin
G, and 5 U/mL streptomycin. Cells at passages 3–6 at the
initiation of the experiments were used. Eight weeks before
the termination of the experiments, the medium in the
25 mM high glucose (HG) experimental groups was changed
to a similar one with or without Glib (Sigma Chemical
Co., St. Louis, MO, USA), while the control group was
continuously grown in 5 mM glucose. Forty-eight hours
before the end of the experiments media were changed to one
of the same composition but containing 1% FBS. Cell layers
were scraped in a nondenaturing lysis buﬀer [4]. Samples
were homogenized, centrifuged, and the supernatant used
for determination of DNA content. For protein analyses, cell
layers were obtained as previously described [4].
2.2. RNA Extraction and Quantitative RT-PCR. Total RNA
was isolated from cell homogenates using the Qiagen RNeasy
Mini Kit (Qiagen Inc., Valencia, CA, USA), according to
the manufacturer’s instructions. The measurement of gene
expression in MC was by one-step RT-PCR with specific
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FRET probes using a multiplex mode in a LightCycler (Roche
Molecular Biochemicals, Manheim, Germany). Primers and
probes for α-2(IV) collagen and PAI-1 quantification were
obtained from Roche Pharmaceuticals (Indianapolis, IN,
USA) and TIB Molbiol LCC (Adelphia, NJ, USA), respectively. β-actin was used as reference gene.
2.3. Immunoblotting. Equal amounts of protein were loaded
and separated on 10% SDS-polyacrylamide gels and blotted
as in our previous studies [4]. MMP-2 and β tubulin
were identified by reaction with the following antibodies: monoclonal mouse anti-MMP-2 (Chemicon, Temecula,
CA, USA), and polyclonal rabbit β tubulin (Santa Cruz).
Immunoreactive bands were visualized with ECL detection
reagent and exposure to Hyperfilm (GE Healthcare, UK).
Band densities were quantified by scanning and normalizing
the densitometric values to that of β tubulin.
2.4. Enzyme-Linked Immunosorbent Assay (ELISA). The concentration of collagen IV in 48-hour conditioned media was
determined in 96 well plates (Microfluor 2, Thermoelectron
Corporation, Milford, MA, USA) by a high sensitivity direct
ELISA [4]. Conditioned media PAI-1 protein was measured
using a commercially available ELISA kit (Aniara, Mason,
OH, USA) following the manufacturers’ instructions.
2.5. Enzyme Immunoassay for Cellular cAMP. MC were
seeded in 96-well plates and grown for 28 hours in 15% FBS
followed by an 18-hour period in 1% FBS. Cultures were
studied before and after treatment with the adenylyl cyclase
activator forskolin with and without pretreatment with the
nonselective phosphodiesterase (PDE) inhibitor 3-isobutyl1-methylxanthine (IBMX, 0.5 mM). Intracellular cAMP was
determined using the Direct Biotrak Enzyme Immunoassay
system of Amersham Biosciences (Piscataway, NJ, USA).
2.6. Protein Kinase-A (PKA) Activity Assay. PKA activity
determinations were carried out using a commercially available kit (Stress X press, Assay Designs, Ann Arbor, MI, USA)
according to the manufacturer’s instructions. Nonspecific
activity was measured by the addition of 10 μM peptide
inhibitor of cAMP-dependent protein kinase (PKI) that is
selective for the catalytic subunit of PKA [17].
2.7. Zymography. MC were seeded in 6-well plates and grown
for 72 hours and then were replaced by 1 mL/well of media
lacking FBS and containing 0.2% lactalbumin. Conditioned
media was obtained at 24 hours and 48 hours. Zymography
was carried out as described [18]. Results were factored by
the DNA content in the corresponding culture well.
2.8. Total Protein and DNA Assays. Protein measurement
was carried out by a modified Lowry method that is free
of interference from lysis buﬀer components [19]. DNA was
measured by a fluorescence method using the PicoGreen
dsDNA kit (Molecular Probes, Inc., Eugene, OR, USA)
according to the manufacturer’s directions.

Experimental Diabetes Research

3

Collagen IV mRNA
0.5

†

PAI-1 mRNA

∗

§
∗

∗

¶

PAI-1/β-actin

α-2(IV) collagen/β-actin

0.3

0.2

†

0.3

0.1
0.1

0

0
(a)

1

(b)

Collagen IV protein
§

16

¶
§
‡

0.8

PAI-1 protein

§
∗

∗

‡
†

ng/μg DNA

ng/μg DNA

12
0.6

0.4

8

0.2
4

0
Glibenclamide
(μM)

0

Glucose (mM)

5

0

0.01

1

25

∗P

< 0.001 versus 5 mM glucose
< 0.001 versus 5 mM glucose
§ P < 0.001 versus 25 mM glucose
‡ P = 0.016 versus 25 mM glucose
¶ P < 0.013 versus 25 mM glucose + 0.01 μM glibenclamide
†P

(c)

0
Glibenclamide
(μM)
Glucose (mM)

0

0

0.01

1

25

5

∗P

< 0.001 versus 5 mM glucose
< 0.001 versus 25 mM glucose
§ P < 0.001 versus 25 mM glucose + 0.01 μM glibenclamide
†P

(d)

Figure 1: Gene and protein expression of collagen IV and PAI-1 in rat mesangial cells after chronic exposure (8 weeks) to high glucose
with and without treatment with glibenclamide. The PAI-1 assay used reacts with latent, active, and inactive PAI-1. Results were factored
by number of cells according to DNA content in the cell layer of the corresponding sample. mRNA n = 17 per experimental group, protein
n = 12 per experimental group.

2.9. Statistical Analysis. Statistical analyses were carried out
using the StatView 5.0.1 software (Abacus Concepts Inc.,
Berkeley, CA, USA). Except where indicated, results were
expressed as means ± SE. Significance was determined

by ANOVA and diﬀerences between groups were determined by a Fisher’s protected least significant diﬀerence
test post-hoc. Statistical significance was set at the 5%
level.
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Figure 2: Total intracellular cAMP content in rat mesangial cells after chronic exposure (8 weeks) to high glucose with and without treatment
with glibenclamide. Determinations were done under basal conditions and after 5 minutes treatment with 10 μM of the adenylyl cyclase
activator forskolin, with or without a 15-minute preincubation with 0.5 mM phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX) to evaluate the role of PDE activity on cAMP accumulation. n = 7 per experimental group.

3. Results and Discussion
3.1. Eﬀects of Glib on the HG-Enhanced Collagen IV and
PAI-1 mRNA Expression and Protein Accumulation. Previous
work by us and others in MC has shown brisk synthesis and
breakdown of newly formed collagen, achieving steady-state
medium concentrations within 24 hours [20, 21]. Therefore,
the results presented here in 48-hours conditioned medium

reflect collagen turnover activity under steady-state conditions. In the medium of MC chronically exposed to HG,
collagen IV protein accumulated 36% over values in 5 mM
glucose controls (Figure 1). However, this was not associated
with a significant increase in collagen IV mRNA indicating,
as previously suggested for collagen I [4], that it could
be the result of decreased catabolism. Chronic treatment
with low-concentration Glib (0.01 μM) in cells grown in
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3.2. Eﬀects of HG and Glib on Cellular cAMP. Cyclic
nucleotide analogs or agents that elevate cellular cAMP have
been demonstrated to downregulate PAI-1 activity and/or
PAI-1 mRNA expression in numerous cell culture systems
[31, 32]. Under steady-state basal conditions MC exposed to
HG contained one-half the amount of cAMP than controls,
and treatment with 0.01 μM Glib fully prevented this change
(Figure 2). Stimulation of cAMP formation with forskolin
increased cAMP 4.5-fold in controls but only 2.7-fold in HGexposed cells. In HG conditions, 0.01 μM Glib resulted in a
forskolin stimulation of cAMP well above that in nontreated,
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HG increased collagen IV mRNA expression over that in
both 5 mM controls and HG-exposed cells. Paradoxically,
however, this treatment resulted in reduction in protein
medium accumulation to control levels (Figure 1). This
suggests enhanced turnover, that is, while Glib stimulates collagen formation it also enhances its breakdown to a greater
extent. As previously shown [16], Glib demonstrated a
biphasic eﬀect at high medium concentrations (1.0 μM) with
unchanged collagen IV mRNA expression and attenuated
decrease in protein accumulation (Figure 1). Previous doseresponse studies demonstrated similar results for collagen I
with intermediate eﬀects with 0.1 μM Glib [16].
We have demonstrated increased glucose transport
and/or enhanced GLUT1 expression in MC treated with
either high or low concentrations of sulfonylureas [15, 16].
Since GLUT1 overexpression and increased glucose transport
in MC leads to exaggerated collagen I and collagen IV protein
synthesis and accumulation [22], it is likely that the Glibstimulated collagen IV mRNA is related to increased glucose
uptake and associated with enhanced collagen IV protein
synthesis.
PAI-1 is the primary inhibitor of plasminogen activators
(PA) thus interfering with the generation of plasmin and its
activation of MMP [23]. Because PAI-1 is increased in pathological conditions such as glomerulosclerosis and kidney
fibrosis, the PA/PAI-1 reaction has been proposed as a novel
therapeutic option for prevention and treatment of chronic
kidney diseases [24]. Renal PAI-1 mRNA is overexpressed
in experimental diabetes [25] and PAI-1 deficiency slows
the progression of the renal disease [26, 27]. Further, HG
upregulates PAI-1 protein expression in MC [28].
As in previous studies [16], HG induced MC overexpression of PAI-1 mRNA with parallel increases in protein
(Figure 1). This overexpression was nullified by 0.01 μM Glib
(Figure 1), supporting the premise that the Glib prevention
of the HG-induced collagen IV accumulation was due
to increased collagen IV catabolism. However, high Glib
concentration was without eﬀect on the HG-enhanced PAI-1
mRNA and protein expression (Figure 1).
Notably, the eﬀects of 0.01 μM Glib on MC collagen IV
metabolism were obtained at a concentration that is equal
or less than that achieved in humans treated with low doses
of the drug. In humans, following an oral dose of 1.75 mg
or 7 mg (usual therapeutic range 1.25–20 mg/day), peak
plasma levels at 90–120 minutes are 0.251 μM and 0.686 μM,
respectively [29, 30]. Therefore, the results obtained in Glibtreated MC in culture are clinically relevant.
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Figure 3: Total intracellular cAMP-dependent PKA phosphorylating activity in rat mesangial cell lysates after chronic exposure
(8 weeks) to high glucose with and without treatment with
glibenclamide. Determinations were done under basal conditions
and after 60 minutes treatment with 20 μM of cAMP. Results
are the diﬀerence between total phosphorylating activity and the
phosphorylating activity in duplicate samples analyzed in the
presence of 10 μM peptide inhibitor of cAMP-dependent protein
kinase (PKI). n = 7 per experimental group.

HG-exposed cells (3.6-fold) but without reaching the stimulated levels in untreated controls (Figure 2). In controls,
forskolin treatment during inhibition of cAMP degradation
with IBMX resulted in 27-fold greater cAMP content over
basal values. In HG-exposed cells, this inhibition of cAMP
degradation induced a greater increase (59-fold) to values
above control (Figure 2). Finally, in HG-exposed, 0.01 μM
Glib-treated cells, inhibition of cAMP degradation during
forskolin stimulation resulted in a cAMP increase to levels
above both untreated control and untreated, HG-exposed
cells under the same conditions (Figure 2). In HG-exposed,
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Figure 4: MMP2 mRNA, protein expression, and gelatinolytic activity in rat mesangial cells after chronic exposure (8 weeks) to high glucose
with and without treatment with glibenclamide. Gelatinolytic activity was measured in 24- and 48-hour conditioned media. Protein and
gelatinolytic activities are expressed relative to control. Zymography results were expressed as total amount of MMP2 determined by the
sum of the area under both MMP2 and pro-MMP2 bands. mRNA n = 12, protein n = 4, zymography n = 12, per experimental group.

1.0 μM Glib-treated cells, basal, stimulated and degradationblocked cAMP values were in all cases lower that in 0.01 μM
Glib-treated cells.
The results above suggest that chronic exposure to
HG induces depressed cAMP generation that is caused by

enhanced PDE activity since its inhibition during adenylyl
cyclase activation restores cAMP to levels above controls. As
shown by the eﬀects of forskolin and IBMX, the presence of
0.01 μM Glib prevents the HG-induced changes by restoring
adenylyl cyclase synthetic activity and modulating PDE
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degradation of cAMP. Therefore, these findings are compatible with a Glib-induced increase in cAMP bioavailability that
downregulates PAI-1.
3.3. Eﬀects of HG and Glib on PKA Activity. The eﬀects of
HG and Glib on PKA activity were next investigated because
although PKA is the major target of cAMP-regulated signal
transduction reactions, there are also pathways that are PKAindependent [33].
cAMP-dependent PKA activity was assessed as the PKIinhibitable phosphorylating activity under basal conditions
and after stimulation with exogenous cAMP. Basal PKA
activity was reduced in cells exposed to HG while treatment with 0.01 μM Glib completely prevented this change
(Figure 3). cAMP increased PKA activity in all groups by at
least 97-fold (Figure 3). In HG exposed cells, this stimulation
increased activity to levels similar to those in stimulated
controls. However, the presence of 0.01 μM Glib induced
an additional increment that was significantly above control
and HG groups (Figure 3). Treatment with 1.0 μM Glib
did not alter the change in PKA activity induced by HG
(Figure 3). These results indicate that in HG conditions, low
concentration Glib maintains a normal basal PKA activity
and under conditions of activation, it permits an added
cAMP-dependent PKA phosphorylating capacity.
The findings above suggest that the repression of PAI-1
expression and associated prevention of the HG-induced collagen accumulation induced by low concentrations of Glib is
mediated by the activity of a cAMP-dependent PKA pathway.
3.4. Eﬀects of HG and Glib on MMP2 Expression and
Gelatinolytic Activity. To demonstrate that the Glib-induced
decrease in PAI-1 expression subserved the decrease in
collagen IV accumulation, the expression of MMP2 and
its gelatinolytic capacity were determined. MMP2 (72-kDa
gelatinase A) is the principal MMP formed by MC in situ and
in tissue culture and mesangial ECM degradation depends
on the activity of the tPA-plasmin-MMP2 cascade [34, 35].
As previously reported [36], HG induced a small increase
in MC MMP2 gene expression (Figure 4). However, this did
not translate into significant changes in protein expression
or gelatinolytic activity (Figures 4 and 5). The presence of
0.01 μM Glib in HG cultures induced marked increases in
MMP2 mRNA, MMP2 protein, and gelatinolytic activity
in both 24- and 48-hour conditioned media over values
in control and HG-exposed cells (Figures 4 and 5). In
contrast, the presence of 1.0 μM Glib in HG cultures,
although inducing upregulation of MMP2 mRNA, did not
change protein expression and gelatinolytic activity was only
modestly increased in 48-hour conditioned medium and to
a lesser extent than for 0.01 μM Glib-HG cultures (Figure 4).
Finally, treatment with 0.01 μM Glib in 5 mM glucose grown
cells did not alter gelatinolytic activity (Figures 4 and 5).
In contrast to results in this study, previous work
demonstrated significantly decreased MMP2 expression in
HG-exposed MC [37, 38] and depressed MMP expression
and activity in glomeruli of diabetic rats [39]. However,
MMP2 mRNA increases are reportedly inconsistent [40,
41]. We and others have also shown that MC exposed
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to HG increase ECM turnover and degradation but with
a net balance of accumulation [6, 35]. In any event,
multiple interventions that ameliorate diabetic nephropathy
are associated with increased MMP2 activity, including
treatment with angiotensin converting enzyme inhibitors
[42], angiotensin II receptor antagonists [43], peroxisome
proliferator-activated receptor-γ agonists [41], and 17βestradiol [44].
Studies have shown that the cAMP analogue 8-bromocAMP increased MMP2 mRNA levels in cultured rat mesangial cells [45]. In addition, forskolin reportedly increased
MMP2 mRNA in JAR human choriocarcinoma cells [46].
Although tPA-plasmin-MMP2 cascade plays a pivotal role
in mesangial ECM degradation, we cannot exclude the
possibility that low concentration Glib-induced increase in
cAMP could directly activate MMP2, which needs further
investigation.
Notably, all the demonstrated metabolic eﬀects of Glib
leading to the prevention of HG-induced collagen IV
accumulation were minimized or not evident using 100fold greater concentration of the sulfonylurea. This biphasic
eﬀect of Glib is not uncommon in the mode of action of
some drugs [47]. In the case of sulfonylureas, it is likely a
consequence of the marked heterogeneity of KATP channels,
their diverse sulfonylurea aﬃnities, and unique metabolic
actions [8]. MC contain at least two distinct KATP channels,
thus, diﬀerent Glib concentrations may stimulate diﬀerent
sets of channels and elicit divergent responses. Finally,
demonstrating reversal of the eﬀects of low concentration
Glib by concomitant treatment with agents that acutely
induce cAMP depletion or PKA inhibition could provide
proof of cause-and-eﬀect. However, this was not attempted
because of interpretative problems arising from specificity of
action and cell viability after the required 8-week period of
continuous treatment.

4. Conclusions
Long-term treatment of MC with low concentration Glib
prevents the HG-induced medium accumulation of collagen
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IV. This eﬀect is likely mediated by a cAMP-PKA-dependent
pathway causing inhibition of PAI-1 expression and concomitant activation of MMP2. Remarkably, low Glib concentration has little metabolic eﬀect in MC cultured under
physiological glucose conditions. It is hypothesized that the
action of Glib is via tissue-specific mesangial KATP channels.
Because the eﬀect of Glib occurs with concentrations/dosages
of the drug within the low range of the human therapeutic
values, the findings presented here bear high clinical significance.
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